Navigation Links
Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
Date:7/25/2012

FORT WORTH, Texas, July 25, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that the results of a 24-week open-label follow-up to the HP802-247 Phase 2b trial will be presented by Robert Kirsner, MD, PhD, on Friday, July 27, 2012, from 3:55-4:15 pm, during the American College of Wound Healing and Tissue Repair held at the Swissotel in Chicago. HP802-247 is an allogeneic living cell bioformulation containing keratinocytes and fibroblasts currently being investigated for the treatment of venous leg ulcers.

Venous leg ulcers affect approximately 2.5 million Americans and are associated with impaired circulation most commonly resulting from damaged veins and/or valves. They typically appear as an open lesion, or ulcer, on the lower extremities, are very slow to heal and often reoccur due to the chronic nature of the underlying disease process.

The Phase 2b trial was designed to determine the potential effectiveness of two cell concentrations and two dosing frequencies of HP802-247, when combined with standard care, compared to control plus standard care, in healing venous leg ulcers over a 12-week treatment period. The study was a randomized, double blind, dose-finding study involving 228 subjects enrolled across 35 investigational centers in the United States. Overall, HP802-247 achieved statistical significance, as compared with control plus standard care, in both the primary and secondary endpoints. HP802-247 was generally well tolerated in the study with the most frequently reported adverse events being skin ulcers, cellulitis, wound infection and skin irritation.  The safety profile of the active groups was similar to the vehicle control.

The 24-week open-label extension of this Phase 2b trial was designed to evaluate the status of the target wound (e.g., open, re-opened or healed), as well as the status of the periwound area following the 12-week treatment period. HP802-247 was not administered to patients durin
'/>"/>

SOURCE Healthpoint Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
2. Robert Farrell Joins Bionovos Board of Directors
3. Engineer Robert J. Wood to receive NSFs Alan T. Waterman Award
4. Fortis Vice President of Nursing Robert Anders Named Academy of Nursing Education Fellow by National League for Nursing
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
7. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
10. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
11. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... TORONTO , Aug. 18, 2014 /PRNewswire/ - SQI Diagnostics ... and commercializes proprietary technologies and products for advanced microarray ... call on Friday, August 22 at 2:00 pm ET.  ... , CEO, will provide a brief review of SQI,s ... Pronovost , a diagnostics industry veteran recently appointed to ...
(Date:8/18/2014)... , August 18, 2014 ... Transparency Market Research "Life Science Reagents Market(Products- PCR ... Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents and Others; End ... Institutions, Clinical Laboratories, and Forensic Laboratories)- Global Industry ... - 2019", the global life science reagents market ...
(Date:8/18/2014)... , 18. August 2014 ... in eine internationale klinische Studie auf, in ... Die Linse soll das Sehvermögen bei allen ... der Operation möglicherweise keine Lese- oder Gleitsichtbrille ... dem Namen FluidVision Accommodating Intraocular Lens ...
(Date:8/15/2014)... FOREST, Ill. , Aug. 15, 2014   ... world,s leading provider of injectable drugs and infusion technologies, ... Morgan Stanley Global Healthcare Conference on Tuesday, Sept. 9, ... The presentation is scheduled to begin at 11:45 ... will be available to all interested parties through a ...
Breaking Biology Technology:SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... YORK, April 17 The market for congestive ... billion in 2007, and is,expected to reach $30 ... by,Kalorama Information, Congestive Heart Failure: Major World Markets, ... three factors: an,increased incidence of CHF, the application ...
... JENA, Germany, April 17 Occlutech GmbH, the leading,European ... a recent news release., In a news release ... opinion from AIPPI the European "Association for the Protection,of ... of,certain European IP held by AGA Medical., AIPPI ...
... April 17 BioMed Realty Trust, Inc.,(NYSE: BMR ... of 5,700,000,shares of common stock at $25.50 per share. ... 22, 2008. Gross proceeds from the offering will be,approximately ... of the,offering to repay a portion of the outstanding ...
Cached Biology Technology:Genomics Likely to Replace Traditional Drug Therapies in Treating CHF 2Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical 2BioMed Realty Trust Prices Public Offering of 5,700,000 Shares of Common Stock 2BioMed Realty Trust Prices Public Offering of 5,700,000 Shares of Common Stock 3
(Date:8/19/2014)... to encourage healthier spending habits? A new study by ... by tracking the purchasing records in a supermarket chain ... nutritional value of foods for sale. , The researchers, ... and Brian Wansink PhD, author of Slim by Design ... Supermarkets in the Northeastern United States between January 2005 ...
(Date:8/19/2014)... the world, leprosy and tuberculosis live side-by-side. Worldwide ... per year, with nearly all of them occurring ... vaccine Bacille Calmette-Guerin, or BCG, provides only partial ... more potent vaccine is needed to combat both ... weapon against both diseases., In a study published ...
(Date:8/19/2014)... (Boston) Some infants born with neonatal abstinence ... a more difficult time going through withdrawal than ... understood. While genetic and epigenetic (when genes are ... identified as potential factors, researchers at Boston University ... (BMC) conducted a first of its kind study ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2
... American scientists have rediscovered a highly distinctive mammal C a ... years ago. Furthermore, it has never before been discovered in ... extinct. , The greater dwarf cloud rat (Carpomys melanurus) has ... eyes, small rounded ears, a broad and blunt snout, and ...
... throughout the sciences in the study of biological, technological, ... to visualize or understand. In a May 1 ... links in networks, Santa Fe Institute (SFI) researchers Aaron ... real-world networks can be understood as a hierarchy of ...
... Iowa and HOUSTON, Texas The first year ... at Iowa State University (ISU) has supported 26 ... to further diversify Americas sources of energy and ... third-largest integrated energy company in the United States, ...
Cached Biology News:Dwarf cloud rat rediscovered after 112 years 2Dwarf cloud rat rediscovered after 112 years 3Nature paper describes technique for extracting hierarchical structure of networks 2Iowa State-ConocoPhillips collaboration advances 26 research projects in first year 2
Whole blood is collected from healthy pigs (mixed breed, either sex) at the time of slaughter, refrigerated within 6 hours, processed within 24 hours and frozen at -20ºC....
... Rhesus Serum • Rhesus serum is collected ... 5-7 years of age. Available Anticoagulants: ... Heparin (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
Reacts with MBP from human, bovine and rat, epitope 129-138. Reacts weakly with rabbit. Does not react with guinea pig....
... DCTD_HUMAN GI Number: 4503277 ... Description: FUNCTION: Supplies the nucleotide ... dCMP + H 2 O = ... Homohexamer. SIMILARITY: Belongs to the Diseases: ...
Biology Products: